• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Mechanism of acquired drug resistance and reversing resist

Research Project

Project/Area Number 05671914
Research Category

Grant-in-Aid for General Scientific Research (C)

Allocation TypeSingle-year Grants
Research Field Laboratory medicine
Research InstitutionTohoku University

Principal Investigator

FUNATO Tadao  Tohoku University, School of Medicine hospital, Lecturer, 医学部附属病院, 講師 (70165455)

Co-Investigator(Kenkyū-buntansha) HOSINO Atsusi  Tohoku University, School of Medicine, Lecturer, 医学部, 講師 (60241600)
KAWAMURA Takeshi  Tohoku University, School of Medicine, Associate proftess., 医学部, 助教授 (80111277)
蝦名 弘子  東北大学, 医学部・附属病院, 文部教官講師 (70223667)
Project Period (FY) 1993 – 1995
Project Status Completed (Fiscal Year 1995)
Budget Amount *help
¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 1995: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1994: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1993: ¥1,100,000 (Direct Cost: ¥1,100,000)
KeywordsAnti-Cancer-drug / Drug-resistance / Antisense / Ribozyme / Colon cancer / Leukemia / Cisplatin / Cytosine arabinoside / サイトシン・アラビノシド / 結腸癌
Research Abstract

Our previous work has focused on implicating fos in the cellular resistance to cancer chemotherapy agents. Our hypothesis, simply standed, is that fos is resposible for directing the cellular respose to DNA damage by activating transcription of genes encoding enzymes involved in DNA synthesis and repair. Inthis study, we have investigated the cisplatin resistance in vitro and in vivo. A hammerhead ribozyme for fos was disigned to cleave selectively only expresed fos RNA the efficacy of an anti-fos ribozyme in reversing this resistant cell lines. The c-fos ribozyme was suppressed fos mRNA in cultured resistant cell line. We demonstrated that expresion of the fos ribozyme sensitivity of A2780DDP cells to antineoplastic agents. On the other hand, the reversal of this resistance is associated with down-regulation of dTMP synthase, DNA polymerase, topoisomerase I and hMT,genes linked to DNA synthesis and repair. Moreover, this fos ribozyme supresed expresion of c-fos gene on implanted tumors in an athymic mice and reversed sensitivity for cisplatin, but not inhibition.

Report

(4 results)
  • 1995 Annual Research Report   Final Research Report Summary
  • 1994 Annual Research Report
  • 1993 Annual Research Report
  • Research Products

    (25 results)

All Other

All Publications (25 results)

  • [Publications] Tone, T.: "Suppression of EJ cells tumorigenicity." in vivo. 7. 471-476 (1993)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Kashani-Sabet, M.: "Suppression of the neoplastic phenotype in vivo by anti-ras ribozyme." Cancer Research. 54. 900-902 (1994)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Ohta, T.: "H-ras ribozyme-mediated alteration of the human melanoma phenotype." Annals of the New York Academy ofSciences. 716. 242-256 (1994)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Funato, T.: "Suppression of H-ras mediated transformation in NIH3T3 cells by a ras ribozyme." Biochemical Pharmacology. 48. 1471-1475 (1994)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] 舩渡 忠男: "ベクターを用いたリボザイムの導入" Drug Delivery System. 10. 91-97 (1995)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] 舩渡 忠男: "PCR法を用いた薬剤耐性発現の早期診断" 臨床病理. 43. 535-539 (1995)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Tone, T.: "Suppression of EJ cells tumorgenicity." in vivo. 7. 471-476 (1993)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Kashani-Sabet, M.: "Suppression of the neoplastic phenotype in vivo by anti-ras ribozyme." Cancer Research. 54. 900-902 (1994)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Ohta, T.: "H-ras ribozyme-mediated alteration of the human melanoma phenotype." Annals of the N.Y.Academy of Sciences. 716. 242-256 (1994)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Funato, T.: "Suppression of H-ras mediated transformation in NIH3T3 cells by a ras ribozyme." Biochemical Pharmacology. 48. 1471-1475 (1994)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Ohta, Y.: "H-ras ribozyme-mediated alteration of the human melanoma phenotype." Annals New York Acade my of Sciences. 716. 242-253 (1994)

    • Related Report
      1995 Annual Research Report
  • [Publications] Funato, T.: "Suppression of H-ras-mediated transformation on NIII313 cells by a rasnibes" Biochemical Pharmacology. 48. 1471-1475 (1994)

    • Related Report
      1995 Annual Research Report
  • [Publications] Kashani-Sabet, M.: "Suppression of the neoplastic phenotype in vivo by an anti-rasriboryme" Cancer Research. 51. 900-902 (1994)

    • Related Report
      1995 Annual Research Report
  • [Publications] 船渡 忠男: "ベクターを用いたリポザイムの導入" Drug Delivery System. 10. 91-97 (1995)

    • Related Report
      1995 Annual Research Report
  • [Publications] 船渡 忠男: "PCR法を用いた薬剤耐性発現の早期診断" 臨床病理. 43. 535-539 (1995)

    • Related Report
      1995 Annual Research Report
  • [Publications] 船渡 忠男: "リボザイムによる抗癌剤耐性克服" 臨床薬理の進歩. 16. 117-121 (1996)

    • Related Report
      1995 Annual Research Report
  • [Publications] Kasani-Sabet,M,Funato,et al.: "Suppression of the Neoplastic Phenotype in Vivo by on Anii-ras Ribozyme" Cancer Reserch. 54. 900-902 (1994)

    • Related Report
      1994 Annual Research Report
  • [Publications] Funato,T,et al.: "Suppression of H-ras Mediated Transformation in NIH3T Cells by ArasR" Biochemical Pharmacology. 48. 1471-1475 (1994)

    • Related Report
      1994 Annual Research Report
  • [Publications] 船渡忠男,他: "アンチセンス・リボザイムによる遺伝子発現抑制作用の電気泳動的分析" 生物物理化学. 38. 237-241 (1994)

    • Related Report
      1994 Annual Research Report
  • [Publications] 船渡忠男: "RASリボザイムを用いた腫瘍細胞の増殖抑制" 血液・腫瘍科. 28. 369-375 (1994)

    • Related Report
      1994 Annual Research Report
  • [Publications] 船渡忠男: "ベクターを用いたアンチセンス・リボザイムの導入法" 日本DDS学会誌. 発表予定. (1995)

    • Related Report
      1994 Annual Research Report
  • [Publications] 船渡忠男: "PCR法を用いた薬剤耐性発現の早期診断" 臨床病理. 発表予定. (1995)

    • Related Report
      1994 Annual Research Report
  • [Publications] Tone,T,Kashani-Sabet,M,Funato,T.et al.: "Suppression of EJ cells tumorigenicity." in vivo. 7. 471-476 (1993)

    • Related Report
      1993 Annual Research Report
  • [Publications] Ohta,Y,Tone,T,Shitara,T,Funato,T,et al.: "H-ras ribozyme-mediated alteration of the human melanoma phenotype." New York Academy of Sciences. (発表予定).

    • Related Report
      1993 Annual Research Report
  • [Publications] 舩渡忠男: "リボザイムによる抗癌剤耐性克服の試み" 癌と化学療法. 21. 336-342 (1994)

    • Related Report
      1993 Annual Research Report

URL: 

Published: 1993-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi